Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College; Guangzhou Research Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou, PR China.
J Thorac Dis. 2009 Dec;1(1):55-62.
Non-small cell lung cancer (NSCLC) accounts for the largest number of cancer deaths annually, worldwide. It seems reasonable to test a less toxic regimen also in early stages after complete (R0) resection of the tumor, where reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and hence perhaps improve survival. The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of patients without dose limiting toxicities or premature treatment withdrawal or death-of administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin immediately post-VATS (video-assisted thoracic surgery) in patients with completely resected NSCLC.
非小细胞肺癌(NSCLC)是全球范围内每年导致癌症死亡人数最多的癌症。在肿瘤完全切除(R0)后,早期阶段进行毒性较小的治疗似乎也是合理的,因为降低毒性可能会提高药物输送的可行性、患者的依从性和治疗的便利性,从而可能提高生存率。本 II 期试验的主要目的是评估在完全切除的 NSCLC 患者中,在 VATS(电视辅助胸腔镜手术)后立即给予培美曲塞联合奥沙利铂辅助化疗的临床可行性,主要终点为无剂量限制毒性或过早治疗终止或死亡的患者比例。